Key result
Dapagliflozin fails to reduce early atrial tachyarrhythmia recurrence following catheter ablation.
Answers are grounded in this paper and cite their sources.
Should not yet change post-ablation SGLT2i management; leaves open whether prior null findings reflect true lack of efficacy or underpowered trial design.
Commentary Can we conclude that dapagliflozin does not reduce early recurrence of atrial tachyarrhythmias after catheter ablation? Juan Tamargo, Eva Delpón
No takes yet. Share an insight, caveat, or question.
Tamargo et al. (2026) studied this question. Dapagliflozin is evaluated in this commentary regarding whether it fails to reduce early recurrence of atrial tachyarrhythmias after catheter ablation.
Synapse has enriched 10 related papers. Consider them for comparative context: